. Author manuscript; available in PMC: 2016 Oct 1.

Published in final edited form as: Clin Cancer Res. 2015 Oct 1;21(19 Suppl):S1–128. doi: 10.1158/1078-0432.CCR-15-1846

Table 1. Newly FDA-Approved Medical Products for the Prevention, Treatment, and Imaging of Cancer: Aug. 1, 2014-July 31, 2015.

ANGIOGENESIS INHIBITORS
Approved Indication	Generic Name	Trade Name	Formulation
certain forms of cervical, ovarian, fallopian tube, and peritoneal cancers^*	bevacizumab	Avastin
certain type of thyroid cancer	lenvatinib	Lenvima
certain forms of colorectal and lung cancers^*	ramucirumab	Cyramza
BONE REMODELING INHIBITORS
Approved Indication	Generic Name	Trade Name	Formulation
potentially lethal complication of advanced cancers^*	denosumab	Xgeva
CELL SIGNALING INHIBITORS
Approved Indication	Generic Name	Trade Name	Formulation
certain type of lung cancer^*	gefitinib^**	Iressa
certain type of non-Hodgkin lymphoma^*	ibrutinib^†	Imbruvica
certain type of breast cancer	palbociclib^†^∧	Ibrance
most common type of skin cancer	sonidegib	Odomzo
DNA REPAIR INHIBITOR
Approved Indication	Generic Name	Trade Name	Formulation
certain type of ovarian cancer	olaparib^**^∧	Lynparza
EPIGENOME-MODIFYING AGENTS
Approved Indication	Generic Name	Trade Name	Formulation
multiple myeloma	panobinostat	Farydak
IMMUNOTHERAPEUTICS
Approved Indication	Generic Name	Trade Name	Formulation
certain type of leukemia	blinatumomab^†^∧	Blincyto
neuroblastoma	dinutuximab	Unituxin
melanoma, certain type of lung cancer	nivolumab^†	Opdivo
melanoma	pembrolizumab^†	Keytruda
IMAGING AGENTS
Approved Indication	Generic Name	Trade Name	Formulation
lymphatic mapping in solid tumors^*	technetium 99m tilmanocept	Lymphoseek
CANCER SCREENING TESTS
Approved Indication	Generic Name	Trade Name	Formulation
colorectal cancer	none	Cologuard
PREVENTIVE VACCINES
Approved Indication	Generic Name	Trade Name	Formulation
cervical, vulvar, vaginal, and anal cancers	human papillomavirus 9-valent vaccine (types 6, 11, 16, 18, 31, 33, 45, 52, and 58)	Gardasil 9